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Abstract
The gut microbiome is comprised of various types of bacteria, fungi, protozoa, 
and viruses naturally occurring in humans and animals as normal microflora. Gut 
microorganisms are typically host specific, and their number and type vary accord-
ing to different host species and environment. Gut microbes contribute directly 
and/or indirectly to various physiological processes including immune modulation, 
regulation of various neurotransmitter, and hormones, as well as production of 
many antioxidants and metabolites. They also play a role as antibiotic, anti-
inflammatory, anti-diabetic, and anti-carcinogenic agents. Moreover, the ability 
of gut microbes to attenuate various systemic diseases like coronary heart disease, 
irritable bowel syndrome, metabolic diseases like diabetes mellitus, and infectious 
diseases like diarrhea has recently been reported. Current research findings have 
enough evidence to suggest that gut microbiome is a new organ system mainly 
due to the microorganisms’ specific biochemical interaction with their hosts and 
their systemic integration into the host biology. Investigations into the potential 
ability of gut microbiome to influence metabolism inside their host via biochemi-
cal interaction with antibiotics and other drugs has recently been initiated. This 
chapter specifically focuses on the importance of gut microorganisms as a new 
organ system.
Keywords: gut microbiota, probiotics, metabolic disorders, gut health,  
drug metabolism
1. Introduction
Certain microorganisms have the unique ability to populate the human gastroin-
testinal tract and thus generally referred as gut microbiota. Gut microbiota is always 
non-pathological, and hence, the immune system is not triggered because of their 
presence. Humans co-evolved with a huge number of intestinal microbial species 
that offer to the host certain benefits by playing an important role in preventing them 
from pathogenic activities [1]. In addition to metabolic benefits, symbiotic bacteria 
benefit the host with various functions like boosting the immune homeostasis and 
inhibiting the colonization by other pathogenic microorganisms. The ability of sym-
biotic bacteria to inhibit pathogen colonization particularly in the gut is mediated 
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via several mechanisms including direct killing of pathogen, competition for limited 
nutrients, and enhancement of immune responses [2]. The intestinal microorgan-
isms also co-evolved and have strong affiliations and association towards each other. 
In this evolutionary process, the persistent and enduring members of this microflora 
become more competent during unsettling influences and thereby become essential 
for human health [3]. Definite composition of human microbiome varies between 
individuals [4] particularly among lean and obese people. The microbiome is also 
affected by the dietary modifications adapted for the weight loss [5]. Examination of 
metabolic profiles of human infant microbiota revealed that ingestion, storage and 
digestion of dietary lipids were explicitly regulated by the microbiome [6, 7].
The human gut microbial communities are a mixture of microorganisms. The 
classes of microbes that constitute the gut microbiome communities differ between 
hosts. The difference is attributed to factors such as, inability of a microorganism to 
migrate between different hosts, intense environmental conditions inside and outside 
host’s gut and host inconsistency in terms of genotype, diet, and colonization history 
[8]. The co-evolution of humans and their symbiotic microorganism has created 
bilateral interactions which are important for the health of humans, and any genetic or 
ecological change in this bilateral interaction can result in pathological conditions like 
infection [8]. Gut microbial communities are important for diverse host functions, 
including metabolism, fertility, development, immunity, and even antioxidant activi-
ties which promote health and fitness of the host [9–12]. The gut microbiome has a 
much larger genetic variety compared to the genome of the host, e.g., human genome 
is comprised of 20-25,000 genes whereas microbiome inhabiting the body is estimated 
to be in trillions. Almost 1010 microorganisms enter the human body daily and with 
the progress of co-evolution of gut microbes in humans, the capability of microbes to 
exchange their genes and associated functions with the environment are some of the 
main factors leading to host adaptation. Therefore, the “hologenome” model appraises 
the host and its microbes genomes as one unit under assortment [13, 14]. It is acknowl-
edged that host-symbiont co-evolution is accountable for basic biological aspects. 
In this chapter we aim to discuss the importance of gut microbiomes as a new organ 
system because of its association with the genetics and its role in the disease and health 
condition of the host. Moreover, the involvement of these microbiomes in shaping 
the overall health and constructing a symbiotic relationship with their host species is 
discussed as well as the co-evolution of gut microbes with the human body.
2. Inheritance of microbiome
2.1 Microbiome
A microbiome is the community of microbes dwelling collectively in a selected 
habitat. Humans, animals, vegetation, soils, oceans or even buildings have their 
own specific microbiome [15].
2.2 Host genetics and gut microbiome
The human gut environment is extremely complex with a unique ecology which 
comprises of trillion of microbiota with approximately 1.5 kg in mass. By using 
genetic techniques like 16S sequencing, 1000 microorganisms have been identified 
within the gut, with approx. 200 (0.5%) defining the core of the intestine microbi-
ome [16]. These bacteria protect the gut epithelial cells against external pathogens. 
They also help the breakdown of indigestible dietary polysaccharides in the gut and 
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thus supply a quick chain of fatty acids, including acetate, butyrate, and propionate, 
which serve as vital metabolites for direct energy source of intestinal epithelial cells, 
prevention of insulin resistance and modulators of insulin secretion [17] (Figure 1).
The genetic makeup of humans is virtually identical, yet the small differences in 
DNA give rise to remarkable phenotypic assortment across the human population. 
The trillions of microbes inhabit our bodies and create complex, body-habitat-spe-
cific, adaptive ecosystems that are finely tuned to frequently changing host physiol-
ogy [18]. A healthy “functional core” is actually a complement of metabolic and other 
molecular functions that are performed by the microbiome within a particular habitat 
but are not necessarily provided by the same organisms in different people [19].
2.3 Inherited microbiomes
The gastrointestinal tract (GIT) of humans is colonized by a vast variety of 
microbial population that can be understood as a complex and polygenetic trait 
which has been interacting and co-evolved with their host genetic environment 
[20–22]. It was previously considered that fetus lives in a germ free environment in 
the mother womb and the gut microbiota are transferred to the baby from mother’s 
birth canal and body via horizontal transmission only [23]. But advanced researches 
have revealed that microbiota are also vertically transmitted to the infants from 
their mothers [24]. Presence of microbes in the meconium of the babies born by 
cesarean section clearly demonstrates that the gut microbes are not only derived 
after the birth [25, 26]. Moreover, presence of many microbes in the umbilical cord 
blood of the preterm babies and in the amniotic fluid substantiate the findings 
that the fetus in the mother womb is not totally sterile [27, 28]. Many gut bacterial 
genera are shared among the mammal species. The microbiomes of mice show 
strong fidelity throughout the generations and reiterate the intrinsic significance of 
these microorganisms in health.
Figure 1. 
Core human microbiome.
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2.4 Relationship of environment in shaping the microbiome
As mentioned above human intestinal microbiome composition is shaped by 
multiple factors like genetics, diet, environment and lifestyle. Several studies point 
towards stronger contribution by the environmental factors in shaping the gut 
microbial composition compared to the genetic factor [29]. It has also been specu-
lated that gut microbial diversity affects the prediction accuracy for certain human 
traits including glucose and obesity problems, as compared to different animal 
models that use only host genetic and environmental factors [30].
2.5  Co-evolution and co-differentiation of host microbe interaction in exploring 
new drug targets
Horizontal gene transfer (HGT), genomic and metagenomics are possible 
approaches to identify drug targets that may also be considered as an evidence of 
co-evolution of hosts and their symbionts. Symbionts have the capacity to perform 
many metabolic activities including fermentation of dietary carbohydrates, drug 
metabolism, antimicrobial protection and immunomodulation, which is primar-
ily due to the presence of genes in their genome which are missing in mammalian 
genomes. Therefore, horizontal gene transfer mechanisms are potential targets for 
drug discovery that become more evident with the use of gnotobiotics (germ free 
animal) in experimental trial to unveil the microbial function in the complex GIT 
microenvironment, and to investigate how orally administered drugs impact the 
gut microbial ecology in long term. HGT has gained immense interest in medi-
cal field as it contributes to the spreading of antibiotic resistance genes as well 
as it may cause closely related microbial strains to differ drastically in terms of 
clinical parameters [31]. Genetic variation in intestinal microbes may trigger the 
production of metabolites, but it may also generate changes in host’s genome that 
may increase metabolite uptake or prevent their further synthesis. Co-evolution 
may lead to co-differentiation since permanent association of host and symbiont 
lineage can result in diversification [32]. The co-differentiation correlate resem-
blances in the microbial symbiont and the host [33, 34] which can be extended to 
an entire microbial community that passes vertically from host to offspring. Over 
the course of speciation, the microbial communities differentiate as a mirror to 
host phylogeny (such situation would be expected in hosts where parents immu-
nize their offspring with microbial clique, e.g., Koala bear mother inoculate “pap” 
with dropping to shift young one from milk to eucalyptus leaves diet) [35]. Fecal 
microbiome from healthy humans is a mirror of distal gut microbiome which is 
highly rich in genes involved in the vitamin synthesis, breakdown of nutrients, 
and metabolism of xenobiotics as compared to already sequenced human genome 
and microbes genome [4]. The presence of conjugate transposons in gut micro-
biome is another important source of horizontal gene transfer in bacteria [36]. 
The HGT is involved not only in spreading antibiotic resistance genes, but also 
as a source of clinical response of closely related microbial strains of Salmonella 
enterica [37] such as the secretory system type III pathogenicity islands encoded 
by SPI-I and SPI-II (virulence genes are present in pathogenicity islands, and play 
a key role in the pathogenesis of Salmonella infections through invasion in host 
cell. Currently, 12 Salmonella pathogenicity islands have been investigated with 
common motifs) [38].
Novel strategies in drug discovery are being pursued by targeting horizontal 
gene transfer involved in the resistance to antibiotic [39] as well as virulence [40]. 
Targeting virulence factors with Salmonellosis inhibitors causes less damage to indig-
enous microbes compared to traditional antibiotic therapy, less selective pressure 
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for evolution and transfer of resistance and may be more effective against divergent 
organisms that have acquired a particular virulence factor by HGT. Genomic islands 
which are a good source of genes and gene transfer systems are also being targeted 
with small molecule inhibitors that are co-administered with antibiotics to prevent 
resistance factors by targeted pathogenesis during the therapy [41].
2.5.1 Co-evolution of drug transporters in host and microbes
It has been established that the majority of molecules possessing physiological or 
pharmacological features are either transported into and or out of the cells by trans-
porting proteins rather than by a passive transport mechanism where drug mol-
ecules cross cell membranes through solute transporters that are already involved 
in the movement of different metabolic intermediary molecules through channels. 
More than 1000 different types of transporting proteins (transporters) are present 
in humans [42] comprising solute carriers (SLC) and ATP binding cassettes (ABC) 
transporters involved in the transport of a broad range of substrates [43].
Human intestinal peptide transporter 1 (hPepT1) belonging to the proton-cou-
pled oligopeptide transporter (POT) family which is also known as solute carrier 
15A (SLC15A) is present in the enterocytes, the PepT2 (oligopeptide transporter 
2, SLC15A2) in kidney, the PHT1 (peptide histidine transporter 1, SLC15A4) 
in brain and the PHT2 (peptide histidine transporter 2, SLC15A3) located in 
spleen, lungs and thymus. Both hPepT1 and PepT2 mediate the transport of di−/
tri-peptides and a broad range of peptidomimetics in the organisms, whereas 
PHT1 and PHT2 mediate the translocation of histidine and with a few selected 
di- and tri-peptides [44]. The hPepT1, an oligopeptide transporter 1 located in the 
enterocystes of the small intestine, has low affinity and high capacity transporter 
protein to transport 400–800 different dipeptides and tripeptides and drugs like 
ACE’1 (Enalapril) and antiviral (acyclovir) [45]. The hPepT1 is also found in 
microbes like Escherichia coli residing the gut [46, 47] to uptake amino acids and 
on the microbial outer membrane channels (OmpC and OmpF) present in E coli 
[48] S. typhi [49] and H. influenza to uptake small and hydrophilic nutrients pos-
sessing a molecular weight lower than 600 kDa [50, 51].
Passive diffusion and secondary transport mechanisms in bacteria may involve 
uptake of drug into bacterial cytoplasm [52, 53]. In the inner membrane of E. coli, 
four protein transporters (PTR) namely YdgR or permease A (DtpA), YjdL, YhiP, 
and YbgH have been characterized as family members belonging to POT. Among 
these peptide transporters, the DtpA mediates the transport of dipeptides and tri-
peptides, thereby exhibiting peptide selectivity very similar to the human oligopep-
tide transporter (hPepT1) in gut enterocytes [54, 55]. These findings emphasize the 
potential of modifications of the human physiological state by indirectly modifying 
the microbiome through drugs [56].
3. Microbiome association with diseases
As described above microorganisms present in the gut of the living organisms 
contribute to health or cause disease of these organisms by interplay with their 
immune system. Microbiome is developed at birth according to host interaction 
but later it is evolved and modified by surrounding factors like environmental and 
diet. The variation in genetic expression of different individuals is thought to be 
linked with different microbial composition [57]. Genotype of the host affects the 
composition of gut microbes. Even mutation of a single gene can cause modification 
in the structure of gut microbiota. The exact mechanism of association between 
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the gut microbes and the genotype of host is still unknown. Bifidobacteria are 
highly prevalent beneficial bacteria in gut microbiome and are associated with 
lactase non-persistent genotype. This genotype is responsible for the synthesis of 
lactase enzyme which helps to digest the lactose, present in the milk. Absence of 
this enzyme leads to lactose intolerance in different organisms. So it is important to 
investigate susceptibility of different underlying pathological conditions by study-
ing microbiomes association with genotype and environmental factors that vary 
among different human populations [58].
Different studies showed that metabolic disorders are largely congenital and are 
associated with different microbiomes. For example, gut microbiomes have been 
linked to metabolic disorders and obesity [59].
3.1 Gut microbes and gastrointestinal tract (GIT) diseases
In gut microbiome, dysbiosis (imbalance of microbial flora) can be induced by 
host factors and/or external factors such as the intake of antibiotics, mental and 
physical stress, and nutrients in the diet. Dysbiosis is likely to impair the regular gut 
microbiota and the appearance of pathobionts and the production of metabolites 
which may be dangerous to the host or may deregulate beneficial microbial-derived 
metabolites. The microbial symbiosis has a significant role in the development of 
many diseases [60] such as the gastrointestinal diseases [61, 62], infections [63], 
metabolic disorders, liver diseases [64], autoimmune diseases [65], mental or 
psychological diseases [66] and respiratory diseases [67].
3.1.1 Inflammatory bowel disease
The inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) 
and ulcerative colitis (UC), has for quite some time been suspected to be a host 
reaction to its gut microbiota. CD represents the chronic inflammation of the 
GIT (involving any part from mouth to anus) with idiopathic etiology while UC 
is the chronic inflammation of the large bowel of the GIT with no known cause. 
Numerous aspects of the microbiota’s association in IBD have been inspected in 
recent years. About 10–20% of adults and adolescents worldwide are affected by 
IBD [68]. The precise cause of IBD is unidentified, but it is believed to be a mul-
tifactorial disease. Inflammation, infection, visceral hypersensitivity, immunity, 
genetic factors, motor dysfunction of the GIT as well as psychopathological factors 
are suspected to play a role in its development [69]. Moreover, abnormal gut micro-
biota has been noticed in the IBD patients and in animals with intestinal inflam-
matory disease [70–73]. Some of the metabolically active anaerobic bacteria in the 
colon and terminal part of ileum interact with the immune system of epithelium 
and mucosal layer of the host intestine. Continuous stimulation of these microbial 
antigens promote pathogenic immune responses and may cause defects in the 
barrier functions of mucous layer by killing some beneficial bacteria or by immune 
dysregulation, consequently resulting in UC and CD. Moreover, disrupted micro-
biota structure and function in inflammatory bowel disease intensify the immune 
response of the host causing dysfunction of epithelium and increased permeability 
of the mucous layer of the intestine [74].
It is difficult to identify a single factor responsible of IBD; however, several 
observations have demonstrated a change in the gut microbial composition in IBD 
patients, both CD and UC [70]. Even though the gut microbiota has been recog-
nized as responsible for the IBD establishment in non-predisposed hosts, numerous 
researches have revealed a high rate of pathogenic E. coli in ileal biopsies of CD 
patients [74]. Mycobacterium avium subspecies paratuberculosis is another bacterial 
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species that has been commonly associated with the CD etiology [75]. Also, in 
IBD patients, large quantity of Enterobacteriaceae and a decline in Faecalibacterium 
prausnitzii was demonstrated to be related to the CD confined to the ileum [76]. 
However, it is not yet clear whether the IBD-related changes in the gut microbiota 
are the reason or the result of the disease.
3.1.2 Gastric cancer
For gastric cancer, H. pylori-associated chronic inflammation is considered 
as a risk factor and WHO has classified H. pylori as a class I carcinogen. In about 
660,000 new cases every year of gastric cancer, H. pylori infection is identified 
as the major cause leading to the acid-producing parietal cells loss, and thereby 
prompting the gastric atrophy, metaplasia, dysplasia, and finally the formation of 
carcinoma [77]. The H. pylori elimination before the chronic atrophic gastritis may 
defend against gastric cancer [78]. The cancer-causing risk might be identified with 
the phylogenetic source of the H. pylori strain, host reaction, and host-microorgan-
ism communication [79, 80].
3.1.3 Colorectal cancer
Worldwide, the colorectal cancer (CRC) is the fourth most common cause of 
death associated with cancer [81]. Like other cancers, the CRC is a complex disease 
related to environmental and genetic factors. Ongoing research has proposed that 
gut microbiota assumes a role in the convergence of these factors, likely through 
forming a tumor-advancing environment.
In certain studies, by using a germ-free mice model of adenomatous polyposis 
coli (APC), a markedly reduced incidence of colonic tumor and a lower tumor load 
was revealed when compared to normally raised mice. Further other distinct CRC 
phenotypes such as bleeding from rectum and iron deficiency has also been shown 
with an invasion of inflammatory cells emerging from an intestinal epithelial 
barrier dysfunction. Therefore, it seems that the microbiome and host factors (for 
example, age and genetic predisposition) are important to the CRC growth and 
progression [82].
3.2 Role of gut microbiota in cardiovascular diseases
Cardiovascular and metabolic disorders are collectively known as cardiometa-
bolic diseases and are associated with high morbidity and mortality along with 
significant health care expenditures [83]. The gut-derived and endogenously 
produced endotoxins including indoxyl sulfate, para-cresyl sulfate and lipopoly-
saccharides have been found to be involved in the development of pathological 
conditions ranging from atherosclerosis to cardio-renal failure or dysfunction 
[84, 85]. Furthermore, the development of some complex metabolic disorders 
including insulin resistance and obesity is also associated with differences in the 
composition of gut microbiota [86]. The metabolites L-carnitine, choline and 
phosphatidylcholine are metabolized by intestinal microbiota to generate TMA 
(trimethylamine) which then undergoes oxidation in liver to produce the proath-
erogenic metabolite known as TMAO (trimethylamine-N-oxide). Moreover, in 
atherosclerotic plaques was detected bacterial DNA of the intestinal microbiome 
indicating the direct involvement of intestinal microbiota in the development 
of atherosclerosis. Therefore, inhibition of intestinal microbiota-mediated 
TMAO production through dietary modulation has been suggested as a potential 
approach for treating atherosclerotic cardiovascular diseases [87].  
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In some earlier research studies, a significantly low synthetic capacity to produce 
TMA and TMAO from dietary L-carnitine as well as a subsequent lower plasma 
levels of TMAO have been observed in vegetarians as compared to omnivores. 
Likewise, significant variations in microbial communities have also been reported 
in vegetarians as compared to omnivores [88, 89] suggesting that chronic dietary 
exposure, i.e., omnivores vs. vegetarians, leads to shift of microbial composition 
with a selective advantage for bacterial species having potential for increased 
TMA production, and, thus, may interfere with treatment of atherosclerotic 
cardiovascular diseases.
3.3 Microbiota and integumentary system
The gastrointestinal (GI) system and skin are highly vascularized and 
densely innervated organs with crucial neuroendocrine and immune roles which 
are uniquely related to the normal function of skin [90]. Evidence of bidirec-
tional and intimate connection between the gut and skin health as well as a close 
link between GI health to skin allostasis and homeostasis has been established 
[91]. GI disturbances resulted often in cutaneous manifestations and the GI sys-
tem, especially the gut microbiota, appears to participate in the pathophysiology 
of many inflammatory diseases, i.e., acne, atopic dermatitis and  
psoriasis [92, 93].
3.3.1 Role of the gut microbiota in skin homeostasis
The mechanism by which GI flora exert their effect on skin homeostasis is still 
unknown; however it is postulated that probably such effect may be related to the mod-
ulatory influence of gut commensals on the systemic immunity [94]. Certain gut micro-
biota and their metabolites, i.e., polysaccharide A, retinoic acid from Faecalibacterium 
prausnitzii, Bacteroides fragilis, and bacteria belonging to the Clostridium cluster IV and 
XI potentiate the accumulation of the lymphocytes and regulatory T cells which assist 
in the anti-inflammatory responses [90]. In addition to this immunomodulatory effect 
there is recent evidence that the intestinal microbiota may influence cutaneous pathol-
ogy, physiology and more directly the modification of the immune response by the 
metastasis of gut microbiome and their metabolic activity [95].
In cases of disturbance in intestinal barriers, it was found that intestinal 
bacteria and their metabolites may have the propensity to accumulate in the skin 
and have also access to the bloodstream which ultimately disrupts skin homeo-
stasis. In fact, DNA of intestinal microbes has been separated from the plasma of 
psoriatic patients, thus showing a direct connection between the gut microbiota 
and skin homeostasis [90]. The short chain fatty acids (SCFAs), i.e., acetate, 
butyrate and propionate resulting from the fermentation of the fibers in GIT are 
believed to play an important role in the maintenance of certain skin microbiota 
which consequently affect cutaneous immune defense system. For example, 
propionic acid has an antimicrobial effect against the most common community-
acquired methicillin-resistant Staphylococcus aureus (MRSA). Previous literature 
also demonstrates that SCFAs in skin play an important role in affecting the 
predominant residence of bacteria on normal human skin. It has been found that 
P. acnes and S. epidermidis have higher ability to tolerate the propionic acid than 
other pathogens. Thus, P. acnes and S. epidermis fermentation may have a low risk 
of disrupting the balance of skin microbiome. Altogether, these findings may 
provide supportive evidence for a functional interactive mechanistic approach 
between the skin and gut [96].
9Gut Microbiome: A New Organ System in Body
DOI: http://dx.doi.org/10.5772/intechopen.89634
3.3.2 Dyshomeostasis due to dysbiosis
Intestinal dysbiosis may have the negative potential to affect the skin function 
since gut microbial flora has a huge potential to produce molecules, both harmful 
and beneficial, that could then reach the circulation and influence skin. Metabolic 
products of aromatic amino acids, i.e., p-cresol and free-phenols are considered 
biomarkers of a disturbed gut environment as their production is due to pathogenic 
bacteria such as Clostridium difficile. These metabolites may preferentially accu-
mulate in the skin, enter the circulation blood and disrupt the epidermal differ-
entiation and integrity of the skin barrier [90]. Indeed, high level of p-cresol and 
free-phenols is associated with impaired keratinization and decreased skin hydra-
tion [97]. Also, the intestinal dysbiosis is responsible for the increased permeability 
of epithelium which ultimately modulate the immune response by disrupting their 
balance with immunosuppressive regulatory T cells and thereby triggers the activa-
tion of T cells effectors. It has also been observed that epithelial permeability is 
further enhanced by the pro-inflammatory cytokines and result in chronic systemic 
inflammation [98].
3.4 Gut microbiome and pulmonary health
Infectious diseases of the respiratory tract including pneumonia and influenza 
result in deaths of approximately 3.25 million people annually [99]. The major-
ity of the therapies being used currently are suboptimal because the problems of 
efficiency, toxicity and antibiotic resistance are difficult to overcome [100]. Most of 
the respiratory tract infections represent failure of host’s immune defense. Recently, 
it was suggested that gut microbiota plays a crucial role in the initiation and 
adaptation of the immune response in other distal mucosal sites including lungs. 
Therefore, it is of interest to understand the underlying mechanisms that regulate 
the interplay between lung defense and gastrointestinal tract and how this interac-
tion aids in achieving optimal lung health.
3.4.1 Asthma and allergies
An abnormal T-helper type 2 (Th2) cell responses is often associated with 
asthma and allergies. The Th2 cells are recognized by their ability to synthesize 
inflammatory cytokines including IL-13, IL-9, IL-5 and IL-4 [101] Evidence 
suggests that the development of allergic diseases in lung is directly affected by 
alteration in gut immune response [65]. In fact, a single oral dose of Candida 
albicans administered to antibiotic treated mice resulted in dysbiosis, i.e., an altered 
composition of the gut microbiome. These treated mice exhibited more CD4 cell 
mediated inflammation response in lung after aerosol administration of an allergen 
in comparison to those mice having normal intestinal flora [102], suggesting that an 
immunological predisposition to respiratory allergies can be facilitated by an altered 
gut microbiome. There is also an increasing interest in understanding the role of 
Th9 and Th17 cells in the development of asthma and allergies.
3.4.2 Viral and bacterial respiratory infections
Gut microbiota also plays a critical role in the immune response to respiratory 
tract viral infections like influenza. In infected mice, the CD8 and CD4 T cell 
subpopulations are directly influenced by the intestinal microbiota [103]. It has also 
been suggested that an intact intestinal microbiota is necessary for the expression of 
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pro-inflammatory cytokines including pro-IL-18 and pro-IL-1β, which are essential 
for clearance of influenza [104]. This indicates that microbial signals are provided 
by gut microbiota which are crucial for the shaping and priming the immune 
response to viral pneumonia.
Similar findings regarding the role of gut microbiome in immune response to 
respiratory bacterial infections have also been observed in germ-free mice. These 
mice were found to be more susceptible to pulmonary infection caused by bacterial 
pathogen Klebsiella pneumonia, showing increased levels of IL-10 and suppressed 
recruitment of neutrophil that allows dissemination and growth of pathogens [105].
3.5 Gut microbiome and pregnancy
All systems of the body including maternal microbiome are affected by preg-
nancy. Changes in gut and vaginal microbiome during gestation are of particular 
significance because during vaginal delivery there is vertical transmission of 
microbes to the newborn [106–108]. During pregnancy the vaginal microbiota 
composition changes throughout the gestation period. In addition to vaginal 
microbiome, the maternal intestinal microbiome also undergoes change dur-
ing pregnancy. It has been reported that bacterial diversity decreases in women 
as the pregnancy progresses [107]. Particularly, the ratio of pro-inflammatory 
Proteobacteria, which includes the Streptococcus genus and Enterobacteriaceae family, 
reduces during first and third trimester, while an increase in the anti-inflammatory 
Faecalibacterium prausnitzii occurs during these trimesters of pregnancy. These 
changes in microbiome are independent of body weight during pregnancy, diet, 
antibiotic use and gestational diabetes, suggesting the association of these changes 
with normal physiological pregnancy-related alteration in maternal immune and 
endocrine systems [109].
The consequences of changes in maternal vaginal and gut microbiota on mother 
health are not clear; however, the gestational changes in fecal and vaginal micro-
biota are considered to be important for the adaptive response necessary for protec-
tion as well as to promote the fetus health. These changes also help in providing a 
particular microbial inoculum to the newborn at birth before its exposure to other 
environmental microbes. Also the microbial communities’ composition in maternal 
vagina and gut are not independent of each other. In fact, in pregnant women of 
35–37 weeks of gestation most of bacteria, including species of Bifidobacterium and 
Lactobacillus, are common between vagina and rectum [110].
Some research studies reported that shift in gut microbiota of mother during 
pregnancy may be an adaptive response for the mother and newborn health. In 
mice, an increase in the gut bacteria associated with gestational age, promotes body 
weight gain indicating a co-evolution of these microbes with their hosts during 
pregnancy [107]. Moreover, during vaginal delivery, the vertical transmission of 
these maternal gut microbiomes to the neonate may help the newborn to get an 
immediate access to microbiota at birth [107, 111].
4. Role of gut-microbiome in brain physiology
Both extrinsic and intrinsic factors play an important role to regulate the develop-
ment and maturation of the central nervous system (CNS) in humans. In germ-free 
and antibiotic-treated animals the physiology of the CNS can be affected by neuro-
chemistry as well as by specific microbiota [112]. Evidences for interaction between 
neuropsychiatric and gastrointestinal pathology in humans have been reported in 
different psychiatric conditions including autism, depression and anxiety [113].
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The role of gut-brain interaction in the nervous system development is also recog-
nized. Gut-brain axis actually establishes a relationship between gut-microbiota and 
their interaction with brain leading to changes in the status of the CNS. The dysbiosis 
in microbial species of the gut may lead to induce imbalance in host homeostasis, 
atypical immune signaling and ultimately progression of CNS diseases [114].
The permeable blood brain barrier (BBB) and functional lymphatic vessels resid-
ing in dura meningeal membrane may serve as a gateway for transmission of signals 
[115]. The exposure to several environmental factors can affect the generation of 
neurons during the development of the CNS [113]. It has been suggested that mater-
nal-fetal interface permeability permits regulatory factors from the gut microbiota 
to stimulate Toll-like receptor 2 (TLR2) that helps to promote neural development of 
fetus and also impart its effects on cognitive function during adulthood [116].
The combination of microbial strains (especially the probiotic) can actively 
counteract the deficient neurogenesis which further strengthen the developmental 
link of microbiome to the hippocampal neuronal generation [117]. The brain-blood 
barrier (BBB) is a highly selective and semipermeable barricade that permits the 
passage of neutral, low molecular weight and lipidic soluble molecules [118]. In 
the development of the structural components and growth of vasculature, BBB 
requires arachidonic acid (AA) and decohexaenoic acid (DHA) which are provided 
as polyunsaturated fatty acids (PUFA) by gut microbiome [119]. It has been demon-
strated that the restoration of BBB is possible in germ-free mice by colonization of 
Clostridium tyrobutyricum that produce high level of butyrates [120].
5. Impact of different environmental conditions on gut microbiome
The most important environmental factors that may lead to dysbiosis include (i) 
Physical or psychological stress, (ii) use of antibiotics, and (iii) diet (Figure 2).
5.1 Physical or psychological stress
Stress is usually defined as homeostasis disruption due to physical, psychologi-
cal or environmental stimuli known as stressors leading to adaptive behavioral and 
physiological response in order to restore homeostasis [121]. The effect of both psy-
chological and physical stress on gut microbiome is widely recognized and has been 
observed in both humans as well as animals [122]. Some research conducted in mice 
has shown that the microbial composition in the cecum was altered in response to 
the exposure of a social stressor by placing an aggressive male mouse into the cages 
of non-aggressive mice. Furthermore, the plasma concentration of stress hormones 
such as adrenocorticotropic hormone (ACTH) and corticosterone was found to be 
significantly higher in germ-free mice as compared to specific pathogen-free mice. 
In addition, several stressors including acoustic stress, self-control conditions and 
food deprivation have a negative impact on the gut microbiome resulting in the 
impairment of the immune system [123, 124].
5.2 Use of antibiotics
It has been observed in both humans and animals that the treatment with 
antibiotics can result in a decreased population of beneficial bacteria including 
Lactobacilli and Bifidobacteria along with the increased population of potential 
pathogenic bacteria like Clostridium difficile and the pathogenic yeast Candida 
albicans. The GI symptoms for example diarrhea, abdominal pain, bloating as well 
as yeast infections may occur in response to microbial shifts or dysbiosis. However, 
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more serious and long-lasting consequences have been suggested. For example, it 
was reported that at the end of a 5-day treatment with the antibiotic ciprofloxacin, 
most of the gut bacteria was restored to the pre-treatment levels in 4 weeks, but 
some intestinal bacteria failed to recover even after 6-months. Moreover, a 7-day 
treatment with clindamycin, a drug of choice for treatment of Bacteroides infec-
tions, resulted in disrupted gut microbiome for up to 2 years [125].
5.3 Diet and obesity
Food is metabolized by the gut microbial species to extract nutrients, but some 
microbial species are more efficient in extracting nutrients from food as compared 
to other species. As different individuals have slightly different microbial popula-
tions, it is probable that more nutrients are harvested by some people’s gut microbes 
making them perhaps more prone to become overweight. A high percentage of 
Firmicutes was found in the gut microbiome of genetically obese mice while a high 
percentage of Bacteriodetes were observed in lean mice. Similar observation was 
reported in lean and obese human volunteers. Moreover, it was also seen that the 
obese people who used a low-caloric diet to lose weight, their gut microbiota shifted 
to a similar bacterial population as observed in lean people [125].
6. Conclusions
The human body is a super-organism consisting of 10 times more microbial 
cells than our own body cells. The body’s assortment of microorganisms is mainly 
in gastrointestinal tract, collectively called the gut microbiota. It can be compa-
rable to an organ in because it performs functions necessary for our survival by 
contributing directly and/or indirectly in various physiological processes. For the 
Figure 2. 
Environmental factors influencing gut microbiota.
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past decade, human gut microbiota has been extensively studied as many scientists 
believe that human health mainly depends on microbes that are living on or in 
our body apart from our own genome. Recently, research findings have suggested 
that gut microbiome is evolving as a new organ system mainly due to its specific 
biochemical interaction with its host which affirm its systemic integration into the 
host physiology as gut bacteria are not only critical for regulating gut metabolism, 
but also important for other systems of host including immune system. The focus of 
this chapter was to highlight the importance of gut microorganisms as a new organ 
system and their possible involvement with host systems as well as the metabolism 
of different drugs and nutrients in the gut by these microbes. So, in this chapter, we 
have reviewed opinions of different researchers about the role of gut microbiota in 
maintaining health as well as its contributory role in different ailments. However, 
literature revealed that the involvement of gut microbiota in altering host genetics 
effecting disease progression needs further investigations.
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